Sir: Medium-chain acyl-CoA-dehydrogenase (MCAD) deficiency is an autosomal recessive disorder of mitochondrial betaoxidation of fatty acids. This disorder has been described in cases of sudden infant death (SID). In 1971 R~is~-aen et al. [1] reported in a Finnish family two siblings with hepatic steatosis, and studies of a subsequently born affected sibling showed changes consistent with MCAD deficiency -high urinary excretion of C6-C12 dicarboxylic acids [2] . After the cloning and description of a common mutation (transition A-G in 985 position), a real possibility appeared to study the frequency of this mutation in different populations [3, 4] . Using Guthrie cards Matsubara et al. [5] detected 12 carriers among 479 newborn babies in Britain, five among 353 in Australia, and five among 536 in North America.
Since presymptomatic diagnosis and appropriate dietary management can prevent life-threatening episodes in MCAD deficiency, we decided to estimate the frequency of the common MCAD mutation in a random Finnish population. For this purpose we used DNA extracted from blood samples of 200 subjects from various parts of the country obtained through the Finnish Red Cross Blood Transfusion Service. PCR and the subsequent NCO1 digestion were done according to Matsubara et al. [6] . We detected four heterozygore carriers of this mutation (1 in 50). Since MCAD deficiency is inherited as an autosomal recessive disorder, our figures would predict that the frequency of the disease could be 1 in 10000 in Finland. To our knowledge it is one of the highest levels of frequency of this mutation reported from various populations [5, 7, 8] . A larger screening study will be required to determine the frequency of this mutation more accurately. However, independent investigations using a biochemical approach -determination of C6-C 12 dicarboxylic aciduria and molecular genetics determination of the MCAD mutation (present investigation) indicate that this disorder is present in Finland, and may lie behind some cases of SID. Sir: Partial splenic embolization (PSE) was introduced as an alternative to splenectomy to avoid the risk of postsplenectomy sepsis and to reduce the number of situations in which surgery would be dangerous or not feasible [5] . PSE is an accepted therapy for the treatment of secondary hypersplenism in various disorders, including oesophageal variceal haemorrhage [3] , thalassaemia major [5] , portal hypertension [1] , painful splenomegaly [2] , Gaucher disease [9] , hypersplenism in [5] , and prior to myelosuppressive treatment in hepatocarcinoma and active chronic hepatitis [2, 3] .
As an alternative to surgical splenectomy, PSE was performed on a 7-year-old girl with hereditary spherocytosis and hypersplenism who initially presented with a haemolytic crisis; haemoglobin values of 6.8 g/dl, jaundice and splenomegaly. She needed blood transfusions on two occasions due to persistent anaemia, with Hb values between 6.8-9 g/dl. PSE was performed following the Spigos protocol [8] .
Peripheral blood cell counts were repeated on days I, 3, 7 and 15, and then 1, 3, 6, and 12 months after PSE (see Table  1 ). Abdominal ultrasound 1 month after PSE showed a 17% reduction in spleen size, with embolization of approximaely 75% of the spleen.
Maddison [7] performed the first successful splenic arterial embolization in 1973. The procedure was initially associated with significant morbidity and mortality, but subsequent series report substantially improved results [6] . We performed the embolization technique described by Spigos [1, 3, 6, 8] because it has a very low risk of complications, although Israel et al. [5] recently reported a lower rate of complications using polyvinyl alcohol.
The increase in haemoglobin values found in our patient has been observed in patients affected by other diseases who have required PSE [5] . The thrombocytosis observed in our patient during the first 15 days after PSE that returned to normal values over 3 months, has been previously reported [3, 5] . This increase in platelet count appears to be due to the increase in sequestration in the spleen. There were no modifications in the white cells. The clinical course in our patient was similar to that described by others [3, 6] , with moderate fever for 3 days, mild abdominal pain and vomiting (known as the postembolization syndrome) and alleviated by symptomatic treatment [2] . We did not observe any other complications (e.g. pleural effusion, pancreatitis, pneumonia [1] ).
We attempted to infarct between 70% mad 80% of the splenic parenchyma, as it has been clinically and experimentally demonstrated that a 30% remnant of splenic tissue can provide protection against infection [4] .
We suggest PSE to be an acceptable alternative to splenectomy in a child with hereditary spherocytosis and secondary hypersplenism, owing to the simplicity of the technique, the favourabIe outcome and the absence of complications in our case.
